Recursion Pharmaceuticals, one of the higher-profile companies trying to use artificial intelligence to discover new medicines, is finding that investor enthusiasm for AI hasn't translated into a bargain stock.
According to an analysis published on Yahoo Finance, the company's shares (ticker RXRX) "look fully valued despite AI drug hopes." In plain terms, that means the current price already reflects a lot of optimism — the stock screens as expensive rather than cheap, even after accounting for the promise of its AI-driven approach.
The same analysis notes that Recursion has been trying to rebuild momentum following a steep five-year decline in shareholder returns. So this is a company working to win back investors who have been burned over a multi-year stretch, not one riding a smooth upward trend.
The tension here is a familiar one in the AI era. A compelling story — using machine learning to speed up and de-risk the notoriously slow, costly process of drug discovery — can lift a stock's price. But a high price only pays off for investors if the underlying business eventually delivers results big enough to justify it. According to the report, Recursion's valuation doesn't currently leave much room for that upside; the good news appears to be priced in already.
It's worth flagging what this brief does not cover: the source provided is a single valuation-focused summary, so it doesn't detail Recursion's specific drug programs, revenue, or clinical progress.
Why it matters: Recursion is a test case for whether AI's promise in the lab can actually reward shareholders — and right now, the market seems to be saying the hope is already baked into the price.